
Bavarian Nordic has upgraded its financial guidance for the second time in five days, it reports in a stock exchange notification.
The upgrade is attributed to sales of the company’s monkeypox vaccine. Several countries have placed orders, and Bavarian Nordic states that it is in dialog with more.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app